Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313356098> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4313356098 endingPage "225.1" @default.
- W4313356098 startingPage "225.1" @default.
- W4313356098 abstract "Abstract Herpes zoster (HZ) has high morbidity in older adults. ZV, which is recommended for individuals ≥60 y, is 51% effective against HZ in the 1st 3 y after vaccination; efficacy decreases with the age of the vaccinee; and wanes to ~40% at 5 y. gE/ASO1B is a recombinant adjuvanted vaccine with 97% efficacy against HZ that does not vary with age of the vaccinee and wanes to 87% at 4y. We compared the cell-mediated immunity (CMI) of ZV and gE/ASO1B at 30 d after the last dose of vaccine and at 1 y. Subjects were 50–70+ yoa who never received ZV (1ary) and adults ≥70 yoa who received ZV ≥5 y previously (boosted). Participants received ZV at entry or gE/ASO1B at 0 and 60 d. Blood from days 0, 30 (ZV peak response), 90 (peak gE/ASO1B) and 365 was used to measure CMI to varicella zoster virus (VZV) and to gE by IFNg and IL2 fluorospot [spot forming cells/106 PBMC (SFC)] and by flow cytometry assessing VZV- and gE-specific proliferation and effector (Teff), effector memory (Tem), and central memory (Tcm) outcomes. The higher CMI responses that best distinguished gE/ASO1B from ZV recipients after adjusting for age, gender, prior ZV administration and baseline CMI were: 1) VZV-specific IL2 and gE-specific IL2 and IFNg SFC at peak response (p≤0.004); 2) higher VZV-specific CD8+ and gE-specific CD4+ and CD8+ responses measured by proliferation at peak (p<0.05); 3) higher CD4+ Tcm% and Tem% and lower Teff% at peak response (p≤0.005); 4) higher VZV-specific and gE-specific IL2 and IFNg SFC at 1 y in all gE/ASO1B groups, but only in the boosted ZV group. CMI did not differ among gE/ASO1B recipients by age or prior ZV administration. The higher memory CD4+ and CD8+ responses detected in gE/AS01B recipients might contribute to its superior efficacy and persistence of protection against HZ." @default.
- W4313356098 created "2023-01-06" @default.
- W4313356098 creator A5014152060 @default.
- W4313356098 creator A5015457989 @default.
- W4313356098 creator A5028159725 @default.
- W4313356098 creator A5047930805 @default.
- W4313356098 creator A5051264386 @default.
- W4313356098 creator A5079455826 @default.
- W4313356098 date "2017-05-01" @default.
- W4313356098 modified "2023-10-16" @default.
- W4313356098 title "A comparison of the immunogenicity of a live attenuated herpes zoster vaccine (ZV) and the recombinant gE/AS01B candidate vaccine in older adults" @default.
- W4313356098 doi "https://doi.org/10.4049/jimmunol.198.supp.225.1" @default.
- W4313356098 hasPublicationYear "2017" @default.
- W4313356098 type Work @default.
- W4313356098 citedByCount "2" @default.
- W4313356098 countsByYear W43133560982018 @default.
- W4313356098 crossrefType "journal-article" @default.
- W4313356098 hasAuthorship W4313356098A5014152060 @default.
- W4313356098 hasAuthorship W4313356098A5015457989 @default.
- W4313356098 hasAuthorship W4313356098A5028159725 @default.
- W4313356098 hasAuthorship W4313356098A5047930805 @default.
- W4313356098 hasAuthorship W4313356098A5051264386 @default.
- W4313356098 hasAuthorship W4313356098A5079455826 @default.
- W4313356098 hasConcept C104317684 @default.
- W4313356098 hasConcept C159047783 @default.
- W4313356098 hasConcept C167672396 @default.
- W4313356098 hasConcept C203014093 @default.
- W4313356098 hasConcept C22070199 @default.
- W4313356098 hasConcept C2522874641 @default.
- W4313356098 hasConcept C2776159415 @default.
- W4313356098 hasConcept C2779341262 @default.
- W4313356098 hasConcept C2780868878 @default.
- W4313356098 hasConcept C40767141 @default.
- W4313356098 hasConcept C553184892 @default.
- W4313356098 hasConcept C55493867 @default.
- W4313356098 hasConcept C71924100 @default.
- W4313356098 hasConcept C86803240 @default.
- W4313356098 hasConcept C8891405 @default.
- W4313356098 hasConceptScore W4313356098C104317684 @default.
- W4313356098 hasConceptScore W4313356098C159047783 @default.
- W4313356098 hasConceptScore W4313356098C167672396 @default.
- W4313356098 hasConceptScore W4313356098C203014093 @default.
- W4313356098 hasConceptScore W4313356098C22070199 @default.
- W4313356098 hasConceptScore W4313356098C2522874641 @default.
- W4313356098 hasConceptScore W4313356098C2776159415 @default.
- W4313356098 hasConceptScore W4313356098C2779341262 @default.
- W4313356098 hasConceptScore W4313356098C2780868878 @default.
- W4313356098 hasConceptScore W4313356098C40767141 @default.
- W4313356098 hasConceptScore W4313356098C553184892 @default.
- W4313356098 hasConceptScore W4313356098C55493867 @default.
- W4313356098 hasConceptScore W4313356098C71924100 @default.
- W4313356098 hasConceptScore W4313356098C86803240 @default.
- W4313356098 hasConceptScore W4313356098C8891405 @default.
- W4313356098 hasIssue "1_Supplement" @default.
- W4313356098 hasLocation W43133560981 @default.
- W4313356098 hasOpenAccess W4313356098 @default.
- W4313356098 hasPrimaryLocation W43133560981 @default.
- W4313356098 hasRelatedWork W1024660077 @default.
- W4313356098 hasRelatedWork W1970057644 @default.
- W4313356098 hasRelatedWork W1972215104 @default.
- W4313356098 hasRelatedWork W2055156886 @default.
- W4313356098 hasRelatedWork W2071322149 @default.
- W4313356098 hasRelatedWork W2153434009 @default.
- W4313356098 hasRelatedWork W2503218969 @default.
- W4313356098 hasRelatedWork W2976520252 @default.
- W4313356098 hasRelatedWork W2999915346 @default.
- W4313356098 hasRelatedWork W4288046429 @default.
- W4313356098 hasVolume "198" @default.
- W4313356098 isParatext "false" @default.
- W4313356098 isRetracted "false" @default.
- W4313356098 workType "article" @default.